REGULAR ARTICLE

blood advances

Impact of somatic and germline mutations on the outcome of systemic mastocytosis

Javier I. Muñoz-González,[1-3] María Jara-Acevedo,[2-4] Iván Alvarez-Twose,[3,5] Jason D. Merker,[6] Cristina Teodosio,[7] Yanli Hou,[6] Ana Henriques,[3,5] Krishna M. Roskin,[6] Laura Sanchez-Muñoz,[3,5] Albert G. Tsai,[6] Carolina Caldas,[1-3] Almudena Matito,[3,5] J. Ignacio Sánchez-Gallego,[1-3] Andrea Mayado,[1-3] Noelia Dasilva-Freire,[1-3] Jason R. Gotlib,[8] Luis Escribano,[1-3] Alberto Orfao,[1-3,*] and Andrés C. García-Montero[1-3,*]

[1]Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), CIBERONC, University of Salamanca, Salamanca, Spain; [2]Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; [3]Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; [4]Sequencing Service (NUCLEUS), University of Salamanca, Salamanca, Spain; [5]Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and CIBERONC, Virgen del Valle Hospital, Toledo, Spain; [6]Department of Pathology, Stanford University School of Medicine, Stanford, CA; [7]Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands; and [8]Division of Hematology, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA

Key Points

- About half of the mutations other than *KIT* D816V identified in SM patients were germline in nature.
- Somatic *EZH2* gene mutations provide prognostic information in addition to that of the well-established *S/A/R* gene panel.

Systemic mastocytosis (SM) is a highly heterogeneous disease with indolent and aggressive forms, with the mechanisms leading to malignant transformation still remaining to be elucidated. Here, we investigated the presence and frequency of genetic variants in 34 SM patients with multilineal *KIT* D816V mutations. Initial screening was performed by targeted sequencing of 410 genes in DNA extracted from purified bone marrow cells and hair from 12 patients with nonadvanced SM and 8 patients with advanced SM, followed by whole-genome sequencing (WGS) in 4 cases. Somatic mutations were further investigated in another 14 patients with advanced SM. Despite the fact that no common mutation other than *KIT* D816V was found in WGS analyses, targeted next-generation sequencing identified 67 nonsynonymous genetic variants involving 39 genes. Half of the mutations were somatic (mostly multilineal), whereas the other half were germline variants. The presence of ≥1 multilineal somatic mutation involving genes other than *KIT* D816V, ≥3 germline variants, and ≥1 multilineal mutation in the *SRSF2*, *ASXL1*, *RUNX1*, and/or *EZH2* genes (*S/A/R/E* genes), in addition to skin lesions, splenomegaly, thrombocytopenia, low hemoglobin levels, and increased alkaline phosphatase and β2-microglobulin serum levels, were associated with a poorer patient outcome. However, the presence of ≥1 multilineal mutation, particularly involving *S/A/R/E* genes, was the only independent predictor for progression-free survival and overall survival in our cohort.

Introduction

Systemic mastocytosis (SM) comprises a heterogeneous group of hematological disorders that is characterized by the accumulation of abnormal mast cells (MCs) in multiple tissues that usually include the skin and bone marrow (BM).[1] According to the World Health Organization (WHO) criteria,[2,3] most SM patients (>90%) have indolent SM (ISM) and a normal life expectancy[4-6]; however, a fraction of the patients might present with (or progress to) advanced forms of the disease, such as aggressive SM (ASM), SM associated with another hematological neoplasm (SM-AHN), and, less frequently, MC leukemia (MCL).[3-5,7] The mechanisms leading to malignant transformation of SM remain to be fully elucidated.

Submitted 7 May 2018; accepted 1 October 2018. DOI 10.1182/bloodadvances.2018020628.

*A.O. and A.C.G.-M. contributed equally to this work as joint last authors.

The full-text version of this article contains a data supplement.

© 2018 by The American Society of Hematology

The *KIT* D816V somatic mutation is present in the majority of adult SM patients,[8,9] particularly among ISM and ASM cases.[10] Thus, although this *KIT* mutation might represent the genetic driver of SM, on its own it cannot explain malignant transformation of the disease. However, multilineal involvement of BM hematopoiesis by the *KIT* D816V mutation, found in approximately one third of ISM cases and the great majority of advanced forms of SM,[6,10,11] particularly when this mutation is already present in an early pluripotent precursor cell also involving mesenchymal stem cells (MSCs), significantly enhances the probability of progression from ISM to advanced forms of SM.[12] Altogether, these findings suggest that acquisition of additional genetic alterations along with the *KIT* mutation and/or the existence of a specific genetic background might be required for progression of ISM to more severe forms of the disease.[13-15] Hence, recent studies based on relatively limited gene panels have shown that advanced forms of SM, including 177 of 284 SM-AHN cases, 28 of 284 ASM cases, and 8 of 284 MCL cases,[13,15-18] often carry mutations in genes previously reported to be altered in other myeloid neoplasms,[19-21] in addition to the *KIT* mutation. However, relatively limited information exists about the frequency of mutations in those genes in diagnostic subtypes of SM other than SM-AHN (eg, ISM and smoldering SM [SSM] in addition to ASM and MCL). Also, these mutations have been found in the other hematological neoplasm component of the disease but not in the MC compartment.[22,23] In addition, it remains unknown whether the occurrence of such mutations in an early hematopoietic precursor would also confer a worse prognosis to SM patients, as demonstrated by Jawhar et al for SM-AHN cases[17] and previously reported for *KIT* D816V.[12]

Here, we first investigated the presence and frequency of genetic variants, for a total of 410 genes, on purified BM MCs, maturing neutrophils, and T cells (plus hair in cases with multilineal gene involvement) from 20 SM patients presenting with a multilineal *KIT* D816V mutation, followed by whole genome sequencing (WGS) in 4 cases. In a second step, the somatic mutations identified were investigated in whole BM samples from another 14 advanced SM patients. To define the clonal hierarchy of the genetic variants identified, patients' genomic (g)DNA obtained from different (purified) BM cell populations and hair was sequenced in parallel. Then the number and type of nonsynonymous (coding) genetic variants identified were compared among the distinct diagnostic subtypes of SM and related to patient outcome. Our results show, for the first time, a high frequency of germline mutations in advanced SM, in addition to the previously described somatic mutations, most of which were also found to involve multiple hematopoietic cell lineages. Somatic *EZH2* gene mutations provide prognostic information, in addition to that of the well-established *SRSF2*, *ASXL1*, and/or *RUNX1* (*S/A/R*) gene panel, in our series of SM patients.

Materials and methods

Patients

Overall, 34 patients (15 females and 19 males), 12 with non-advanced SM but high-risk features (ie, ISM with multilineal involvement by the *KIT* D816V mutation and high serum baseline tryptase levels) and 22 with advanced forms of SM (ie, 4 SSM, 11 ASM, and 7 SM-AHN), diagnosed at the reference center (Virgen del Valle Hospital) of the Spanish Network on Mastocytosis (REMA) were studied (median age at diagnosis, 52 years; range, 0-76 years) based on (1) the presence of multilineal *KIT* D816V mutation, including involvement of MSCs in every ISM case tested, (2) high (>100 μg/L) tryptase serum levels, and (3) follow-up time from diagnosis ≥ 1 year (median, 6.5 years; range, 1-48). In an initial series (test series) of 20 patients (12 nonadvanced and 8 advanced SM cases; patients 1-20 in Table 1) sufficient ($\geq 5 \times 10^4$) highly purified BM MCs, maturing neutrophils, and T cells were also required to perform further molecular analyses. In all 20 patients, hair was collected in parallel with the purified BM cell populations. In the additional 14 advanced SM cases (cases 21-34 in Table 1), availability of a whole BM sample was required to enter the study. Diagnosis and classification of SM were reviewed based on 2016 WHO criteria.[2] All patients showed BM MC aggregates in histology with CD25$^+$ *KIT* D816V mutated and cytologically altered BM MCs; in addition, median serum baseline tryptase levels at diagnosis in nonadvanced and advanced SM cases were 268.5 μg/L (range, 115-1298) and 224 μg/L (range, 112-1469), respectively. To detect SM-AHN, conventional WHO cytomorphology and immunophenotypic criteria,[2] based on the EuroFlow ALOT and acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) antibody panels,[24] were used, respectively; at diagnosis, no patient showed BM infiltration by blast cells or other cells (in the absence of pathological MCs) compatible with a non-MC myeloid malignancy. Information about patient treatment is available in supplemental Table 7. Prior to entering the study, each individual gave his/her written informed consent to participate according to the Declaration of Helsinki, and the study was approved by the local institutional Ethics Committees. During the study period, 20 of 34 patients showed disease progression or died from SM-related causes, whereas the remaining 14 cases had stable disease (Table 1), after a median follow-up from initial diagnosis of 6.5 years. Briefly, 9 ISM cases progressed to SSM (n = 3) or ASM (n = 6), 8 ASM patients showed progression to ASM-AHN (n = 6) or died from SM-related causes (n = 2), and 3 SM-AHN patients died from SM-related causes. None of the patients showed progression to MCL, and none of the 34 SM patients had a history of familial mastocytosis.

Purification of BM cell populations

Identification and isolation of antibody-stained (supplemental Table 1) BM MCs, maturing neutrophils, T cells, and MSC populations were performed in the initial cohort of 20 patients, as described in supplemental Methods, using well-established stain-and-then-lyse-and-wash procedures[10] and a 4-way fluorescence-activated cell sorter (FACSAria III) equipped with FACSDiva software (both from BD, San Jose, CA), as described elsewhere.[10,25] The purity of the FACS-sorted cells was systematically >98%, in the absence of cross-contamination by MCs (<0.001%) or any other *KIT* D816V$^+$ BM cell population.

Analysis of the KIT D816V mutation

Positivity for the *KIT* D816V mutation was assessed in gDNA of FACS-purified BM MCs, maturing neutrophils, T cells, and MSCs using a quantitative real-time allele-specific oligonucleotide PCR method, as described.[26,27]

Targeted gDNA sequencing

Overall, 40 ng of gDNA from purified BM MCs and maturing neutrophils was used for targeted sequencing of all exons of 409 genes in a first cohort of 20 cases (patients 1-20 in Table 1). For this purpose, the AmpliSeq Comprehensive Cancer Panel was analyzed

Table 1. Clinical and biological features of the 34 SM patients carrying the multilineal *KIT* mutation analyzed in this study

			Diagnosis					Follow-up (at disease progression or last visit)					
Patient ID	Sex	Age, y	WHO subtype	BM MC aggregates in histology	sBT, ng/mL	Progression	PFS, y	Age, y	WHO subtype	sBT, ng/mL	Alive	OS, y	Cause of progression
1	M	46	ISM	+	115	No	17	63	ISM	105	Yes	17	–
2	M	48	ISM	+	210	No	19	67	ISM	258	Yes	19	–
3	M	67	ISM	+	167	No	3	70	ISM	143	Yes	3	–
4	F	71	ISM	+	208	Yes	5	76	SSM	289	Yes	10	sBT > 200; SPLEN
5	F	39	ISM	+	175	Yes	15	54	SSM	240	Yes	17	sBT > 200; SPLEN
6	M	45	ISM	+	267	Yes	2	46	SSM	310	Yes	9	HEP-SPLEN; DBS
7	M	66	ISM	+	270	Yes	2	68	ASM	305	No	6	HEP-SPLEN; NEUP
8	F	11	ISM	+	1077	Yes	14	25	ASM	1970	Yes	30	HEP-SPLEN*; DBS
9	M	0	ISM	+	332	Yes	32	31	ASM	430	Yes	48	HEP-SPLEN*; DBS
10	M	32	ISM	+	1298	Yes	30	62	ASM	2036	Yes	39	HEP*; DBS
11	M	57	ISM	+	362	Yes	6	63	ASM	1507	No	7	HEP*; IDA
12	F	47	ISM	+	290	Yes	2	49	ASM	312	No	6	SPLEN*; DBS; TRP
Subtotal	66% M, 34% F	46.5 (0-71)			270 (167-1298)	9/12 (75%)	10 (2-32)	62.5 (25-76)		307.5 (105-2036)	9/12 (75%)	13.5 (3-48)	
13	M	51	ASM	+	238	No	6	57	ASM	174	Yes	6	–
14	F	60	ASM	+	260	No	10	70	ASM	288	Yes	10	–
15	M	72	ASM	+	1469	No	4	76	ASM	1469	Yes	4	–
16	M	66	ASM	+	123	Yes	4	70	SM-AHN	53	No	4	MPN
17	F	37	ASM	+	201	Yes	1	38	SM-AHN	NA	Yes	3	AML
18	M	65	ASM	+	150	Yes	3	68	SM-AHN	516	No	4	MDS
19	M	45	ASM	+	548	Yes	4	49	SM-AHN	477	No	10	AML
20	M	58	ASM	+	178	Yes	1	59	SM-AHN	235	No	2	MDS
21	F	76	ASM	+	279	Yes	5	81	ASM	400	No	5	SM-related death
22	F	49	SM-AHN	+	180	No	10	50	SM-AHN	173	Yes	10	–
23	F	41	SM-AHN	+	184	No	3	44	SM-AHN	123	Yes	3	–
24	F	53	SM-AHN	+	159	No	3	56	SM-AHN	85	Yes	3	–
25	F	51	SM-AHN	+	112	Yes	11	62	SM-AHN	147	No	11	SM-related death
26	F	56	SM-AHN	+	1376	Yes	1	57	SM-AHN	1354	No	1	SM-related death
27	M	64	ASM	+	180	Yes	12	76	SM-AHN	107	Yes	12	AML
28	M	70	ASM	+	308	Yes	1	71	ASM	308	No	1	SM-related death
29	M	59	SM-AHN	+	160	Yes	1	60	SM-AHN	257	No	1	SM-related death
30	M	15	SM-AHN	+	210	No	13	28	SM-AHN	107	Yes	13	–
31	F	66	SSM	+	892	No	4	70	SSM	386	Yes	4	–
32	M	41	SSM	+	304	No	18	59	SSM	226	Yes	18	–

Subtotal and total results are expressed as percentage of cases (and range) for sex (male [M]/female [F]); as median (and range) for age, serum baseline tryptase (sBT), PFS, and OS; and as number of cases (and percentage) for progression and survival.

DBS, diffuse bone sclerosis; HEP, hepatomegaly; IDA, iron-deficiency anemia; MPN, myeloproliferative neoplasm; NEUP, neutropenia; SPLEN, splenomegaly; TRP, thrombocytopenia; +, positive; –, no progression.

*With organ failure.

Table 1. (continued)

Patient ID	Sex	Age, y	Diagnosis			Progression	PFS, y	Follow-up (at disease progression or last visit)			Alive	OS, y	Cause of progression
			WHO subtype	BM MC aggregates in histology	sBT, ng/mL			Age, y	WHO subtype	sBT, ng/mL			
33	F	52	SSM	+	316	No	5	57	SSM	282	Yes	5	–
34	F	33	SSM	+	187	No	10	43	SSM	166	Yes	10	–
Subtotal	50% M 50% F	54.5 (15-76)			224 (112-1469)	11/22 (50%)	4 (1-18)	59 (28-81)		235 (53-1469)	13/22 (59%)	4.5 (1-18)	
Total	56% M 44% F	51.5 (0-76)			249 (112-1469)	20/34 (59%)	4 (1-32)	62 (25-81)		282 (53-2036)	22/34 (65%)	6.5 (1-48)	

Subtotal and total results are expressed as percentage of cases (and range) for sex (male [M]/female [F]); as median (and range) for age, serum baseline tryptase (sBT), PFS, and OS; and as number of cases (and percentage) for progression and survival.

DBS, diffuse bone sclerosis; HEP, hepatomegaly; IDA, iron-deficiency anemia; MPN, myeloproliferative neoplasm; NEUP, neutropenia; SPLEN, splenomegaly; TRP, thrombocytopenia; +, positive; –, no progression.

*With organ failure.

on an Ion Proton platform (both from Life Technologies, Carlsbad, CA), according to the manufacturer's instructions. Only those nonsynonymous coding genetic variants identified based on the GRCh37 reference genome[28] with ≥100× allele coverage were selected.

Subsequently, the following additional filters were applied to discriminate between acquired genetic variants (ie, somatic mutations) and germline mutations vs genetic variants present in the Spanish population (ie, single nucleotide polymorphisms). First, the above results were compared with the 5000 exomes,[29] the IBS 1000 Genome Project,[30] and the ExAC[31] population databases. Then, only those genetic variants that had not been previously reported in Spanish and/or in European (non-Finnish) populations and/or those with a minor allele frequency <0.001 were considered in this study. Subsequently, the exome of 36 control gDNA samples representative of the Spanish healthy population (Spanish National DNA Bank Carlos III, University of Salamanca, Salamanca, Spain; http://www.bancoadn.org), pooled into 3 groups of 12 individuals per group, was sequenced to discriminate between the actual genetic variants found in SM patients and technical sequencing artifacts. Then, potentially deleterious mutations, as defined by the SIFT[32] and PolyPhen[33] algorithms, were selected and confirmed by Sanger sequencing on gDNA extracted from purified BM MCs, neutrophils, and T lymphocytes. Finally, the somatic vs germline nature of the genetic variants was evaluated by Sanger sequencing of gDNA obtained from paired patient's hair. Germline mutations were defined as those gene variants detected in gDNA from hair with an allele frequency ~50%. In 1 patient (case 9 in Table 1), the germline nature (vs early acquisition of the mutation during embryonic development) could be tested (and confirmed) in gDNA from his mother's hair. Additionally, the *SRSF2*-p.P95[34] mutational hotspot was investigated through Sanger sequencing of BM-derived gDNA from all 20 patients.

The new mutations identified were classified according to their pattern of distribution in different cell compartments, as follows: (1) hematopoietic (acquired) somatic mutations either restricted to MCs or (2) shared by MCs and other myeloid and/or lymphoid cells (ie, multilineal mutations) and (3) inherited rare germline variants or mutations acquired early during embryonic development, when the genetic variant was also present in gDNA from hair (supplemental Table 2).

Based on the somatic mutations found, a customized library for target sequencing of 15 genes (ie, *ASXL1*, *CDH11*, *DNMT3A*, *EPHA7*, *EZH2*, *ICK*, *IKZF1*, *ITGA10*, *KAT6B*, *PIK3CD*, *ROS1*, *RUNX1*, *SF3B1*, *SRSF2*, and *TET2*) was designed and analyzed in an additional cohort of 14 advanced SM patients (4 SSM, 3 ASM and 7 SM-AHN; patients 21-34 in Table 1). A total of 200 ng of BM gDNA per patient was used to prepare DNA libraries with a TruSeq Custom Amplicon Low Input kit (Illumina, San Diego, CA) and sequenced at 2 × 150-bp read length on an Illumina HiSeq 2500 genome sequencer, following the manufacturer's instructions.

WGS

gDNA from purified BM MCs and T lymphocytes from patients 9, 10, 13, and 14 was used to generate a single short-insert library. Libraries were sequenced on an Illumina HiSeq 2500 instrument to generate paired-end 2 × 100-bp reads at a minimum of 110 G of data per sample (average coverage of 48.4 total reads; range, 41.9-53.9). The raw reads from both cell population libraries were processed and

Table 2. **Number and type of genetic variants identified in purified BM MCs from SM patients by WGS (n = 4)**

Patient ID	SNVs	Indels	Total variants (SNVs + indels)	Mutations per Mb
9	15	7	22	0.008
10	486	15	501	0.18
13	534	21	555	0.19
14	267	9	276	0.10
Average	326	13	339	0.12

Indels, insertions and deletions; SNV, single nucleotide variant.

aligned to the GRCh37/hg19 reference sequence[28] according to GATK best practices.[35] Bulk read statistics were calculated using samtools[36] (version 1.3.1, stats subcommand). Exon coverage was calculated using bedtools[37] (version 2.26.0, coverage subcommand) with exon ranges from UCSC Known Genes[38] downloaded with the UCSC Table Browser.[39] Only those genetic variants with ≥20× allele coverage were considered. Sequencing metrics for each specimen are provided in supplemental Table 3.

Statistical analyses

The Kruskal-Wallis and Mann-Whitney *U* tests were used to assess the statistical significance (set at $P < .05$) of differences observed among groups. Overall survival (OS; calculated from the time of diagnosis to death or the last follow-up visit) and progression-free survival (PFS; calculated from the time of diagnosis to disease progression/death or the last follow-up visit in case of stable disease) curves were plotted according to the Kaplan-Meier method and compared using the Breslow (ie, generalized Wilcoxon) test, as suggested by Bouliotis and Billingham[40] for data with a nonproportional hazard pattern. Receiver operating characteristic curve analysis was used to identify the most sensitive cutoff for the number of genetic variants that discriminated between patients with distinct OS and PFS. For multivariate analyses, the covariate adjustment model[41] was applied to those variables found to be statistically different in the univariate analysis, and the Cox proportional hazard regression model was then used. SPSS software (SPSS version 20.0; IBM Corporation, Armonk, NY) was used for all statistical analyses.

Results

Nonsynonymous coding genetic variants identified in SM patients

In addition to *KIT* D816V, targeted next-generation sequencing (NGS) analyses of purified BM cell populations obtained from the first cohort of 20 SM patients showed 37 583 genetic variants (median: 1347 per case; range: 662-2431) that resulted in 52 nonsynonymous coding genetic variants involving 39 genes, after excluding population allele filters and technical artifacts (supplemental Table 2). Only 10 of 39 genes (*ASXL1*, *DCC*, *DNMT3A*, *EZH2*, *IKZF1*, *LRP1B*, *RUNX1*, *SF3B1*, *SRSF2*, and *TET2*) were recurrently mutated (ie, present in ≥2 patients) (supplemental Table 2). Interestingly, 46% (24/52) of the nonsynonymous coding genetic variants found are reported here for the first time (supplemental Table 2).

Fifteen of the 39 mutated genes harbored half of the genetic variants detected (26/52), which were confirmed to be somatic mutations present in hematopoietic cells but absent in hair gDNA; in contrast, the remaining 24 mutated genes carried germline genetic variants (or early acquired mutations), because they were present at ~50% allele burden in all hematopoietic cells tested and in the patients' hair (supplemental Table 2). Of note, the germline nature of the *IGF2R* mutation in patient 9 was confirmed in gDNA extracted from his mother's hair. Also, most somatic mutations (20/26, 77%) corresponded to multilineal mutations that involved myeloid (17/26, 65%) or myeloid plus lymphoid (3/26, 12%) hematopoietic BM cells, in addition to MCs, and only a few mutations (6/26, 23%) were restricted to the MC compartment in BM (supplemental Table 2).

Subsequent WGS analysis of BM MCs and T cells from 4 ASM cases showed a genome-wide mutation frequency of between 0.008 and 0.19 mutations per megabase (Mb; average of 0.12 mutations per Mb) (Table 2). After applying filters to discriminate for MC-specific genetic variants (supplemental Methods), only 10 nonsynonymous coding or canonical splice site MC-specific variants (range: 0-4 per case) were found (supplemental Table 5). Only 1 of 10 MC-specific genetic variants identified in the *PIK3CD* gene by WGS analysis was also screened by targeted NGS. Interestingly, similar allele burdens were found, despite the distinct sequencing methods used (ie, 33% for WGS and 37% for targeted NGS).

Ten of the 14 advanced SM patients included in the second patient cohort (71%) harbored a total of 15 mutations, other than *KIT* D816V, involving 9 genes, of which 2 (*RUNX1*, *SRSF2*) were recurrently mutated. Interestingly, 5 of these 15 mutations (33%) were reported here for the first time (supplemental Table 3).

Clonal hierarchy of somatic mutations involving hematopoietic cells

All 20 patients screened for mutations within purified BM cell populations showed multilineal involvement of BM hematopoietic cells by *KIT* D816V, and *KIT* D816V–mutated MSCs were detected in 11 of 13 cases tested, including 9 of 9 ISM cases (patients 2, 3, 5, 6, 7, 9, 10, 11, and 12) and 2 of 4 ASM cases (patients 13 and 14). Also, targeted NGS analyses showed that 11 of 20 patients carried additional mutations.

Detailed analysis of the mutated allele burden within the MC population and the different hematopoietic cell lineages involved (supplemental Table 2) revealed heterogeneous patterns of distribution of somatic mutations in hematopoietic cells. Briefly, *KIT* D816V apparently emerged as the first somatic mutation acquired by hematopoietic cells in 4 of 11 cases: patients 5 (ISM), 14 (ASM), 17 (ASM), and 18 (ASM) (supplemental Figure 1A). In 1 ISM patient (patient 7) who had *KIT* and *RUNX1* mutations, the *KIT* mutation was associated with a greater degree of involvement of hematopoiesis (including *KIT* D816V–mutated MSCs), pointing out its potential emergence at an earlier stage than the *RUNX1* mutation; however, lower percentages of mutated MCs for *KIT* vs *RUNX1* (24% vs 50% allele burden, respectively) were observed, which may indicate that the 2 mutations might had been acquired in different clones/subclones, in the absence of chromosomal/genetic gains and/or losses (supplemental Figure 1B). Likewise, a pattern consistent with the coexistence of 2 different clones/subclones was found in 2 other ASM cases (patients 19 and 20) that progressed to ASM-AHN (supplemental Figure 1B). Of note, in patient 19, AML blasts identified at progression tested positive for the *EZH2* mutation but lacked *KIT* D816V. In turn, in another ASM case

Table 3. Number of genes carrying nonsynonymous coding genetic variants (somatic vs germline mutations) per SM patient grouped according to the distinct diagnostic subtypes of the disease

		Hematopoietic acquired somatic mutations														
Patient ID	WHO diagnostic subtype	MC restricted mutations	Mutations, median (range), n	Mutated patients (%)	Multilineal mutations	Mutations, median (range), n	Mutated patients (%)	Total somatic mutations	Mutations, median (range), n	Mutated patients (%)	Germline genetic variants or early acquired mutations	Mutations, median (range), n	Patients with ≥2 mutations (%)	Total genetic variants	Mutations, median (range), n	Patients with ≥3 mutations (%)
1	ISM	–	0 (0-2)	3/12 (25)	–	0 (0-2)	3/12 (25)	–	0 (0-3)	4/12 (33)	–	1 (0-2)	3/12 (25)	–	1 (0-4)	3/12 (25)
2	ISM	–			–			–			1 (*EP400*)			1		
3	ISM	–			–			–			2 (*RECQL4*, *NSD2*)			2		
4	ISM	–			–			–			1 (*DCC*)			1		
5	ISM	1 (*ITGA10*)			–			1			–			1		
6	ISM	–			–			–			–			–		
7	ISM	–			1 (*RUNX1*)			1			2 (*CSF1R*, *MARK4*)			3		
8	ISM	–			–			–			1 (*SYNE1*)			1		
9	ISM	–			–			–			2 (*IGF2R*, *ITPKA*)			2		
10	ISM	–			–			–			1 (*HSP90AA1*)			1		
11	ISM	2 (*EZH2*, *SF3B1*)			1 (*DNMT3A*)			3			–			3		
12	ISM	1 (*IKZF1*)			2 (*ASXL1*, *DNMT3A*)			3			1 (*DCC*)			4		
13	ASM	–	0 (0-1) NS	2/8 (25) NS	–	2 (0-5) $P = .004$	7/8 (88) $P = .008$	–	2 (0-5) $P = .02$	7/8 (88) $P = .02$	1 (*SDHC*)	1 (0-6) NS	3/8 (38) NS	1	3 (1-11) $P = .02$	6/8 (75) $P = .03$
14	ASM	1 (*PIK3CD*)			1 (*EPHA7*)			2			–			2		
15	ASM	–			2 (*EZH2*, *IKZF1*)			2			1 (*DST*)			3		
16	ASM	–			2 (*SRSF2*, *TET2*)			2			1 (*CREBBP*)			3		
17	ASM	1 (*KAT6B*)			2 (*ASXL1*, *RUNX1*)			3			–			3		
18	ASM	–			3 (*EZH2*, *ROS1*, *SF3B1*)			3			3 (*EPHB6*, *LRP1B*, *RPS6KA2*)			6		
19	ASM	–			1 (*EZH2*)			1			3 (*CYP2C19*, *LRP1B*, *TCF3*)			4		
20	ASM	–			5 (*CDH11*, *ICK*, *SRSF2*, *RUNX1*, *TET2*)			5			6 (*ADGRB3*, *MBD1*, *MUC1*, *NFKB2*, *NOTCH4*, *SOCS1*)			11		

Results are expressed as number of genetic variants per case after classifying the genetic variants into hematopoietic restricted mutations and germline genetic variants or early acquired mutations (ie, during embryonic development).
NS, not statistically significantly different.

(patient 16) that progressed to ASM-AHN, *KIT* D816V was a secondary event to the *TET2* mutation (supplemental Figure 1C). Finally, in 2 ISM cases (patients 11 and 12) and 1 ASM case (patient 15), the precise clonal hierarchy could not be defined with the available data.

Mutational profiles in ISM vs ASM

A higher median number of nonsynonymous coding genetic variants per patient was detected in ASM (median, 3 mutations per case; range, 1-11 mutations per case) compared with ISM (median, 1 mutation per case; range, 0-4 mutations per case; P = .02) (Table 3). Likewise, similar differences were also found when we restricted the analysis to the number of somatic mutations that involved multiple BM hematopoietic cell lineages (Table 3): 3 of 12 ISM cases (25%) vs 7 of 8 ASM cases (88%) (P = .008). In contrast, similar numbers of somatic mutations restricted to the MC compartment in the BM and of germline mutations/variants were observed in ISM vs ASM patients (Table 3).

Impact of the mutational profile on the outcome of SM

Receiver operating characteristic curve analysis showed that the presence of ≥3 genetic variants in genes other than *KIT* was the most sensitive cutoff for discriminating between patients with distinct OS and PFS. Thus, SM patients who carried ≥3 nonsynonymous coding genetic variants other than *KIT* D816V showed a significantly shortened PFS (median: 3 vs 30 years) and OS (median: 6 years vs not reached) compared with patients with <3 mutations (P = .002 and P < .001, respectively) (Figure 1A). Similarly, the presence of ≥3 germline variants was also associated with a shorter PFS (median, 3 vs 14 years) and OS (median, 4 years vs not reached) compared with cases with <3 germline variants (P = .016 and P = .004, respectively) (Figure 1B), whereas the presence of ≥1 somatic mutation (other than *KIT* D816V) involving multiple hematopoietic cell lineages showed an adverse impact on PFS (median, 3 vs 30 years) and OS (median: 6 years vs not reached) compared with the absence of somatic mutations other than *KIT* D816V (P = .009 and P = .001, respectively) (Figure 1C). In contrast, the presence of somatic mutations (other than *KIT* D816V) restricted to the MC compartment showed no prognostic impact on PFS or on OS of SM patients (Figure 1D).

Interestingly, when we restricted the analysis to those mutations involving the *SRSF2*, *ASXL1* and/or *RUNX1* (*S/A/R*) gene panel[2,17] among all 34 SM patients, a significant impact on PFS and OS (P < .001 and P = .002, respectively) was also observed (Table 4; Figure 2A). Interestingly, the status of the *EZH2* gene (ie, the most frequently mutated gene among our patients) in *S/A/R*-negative patients further identified, among *S/A/R*-nonmutated cases, 2 patient groups with distinct outcomes (Figure 2B). Hence, ≥1 mutation in the new *SRSF2*, *ASXL1*, *RUNX1*, and/or *EZH2* (*S/A/R/E*) gene panel showed an increased significant impact on PFS (P < .001) and OS (P < .001) vs *S/A/R* genes alone (Table 4; Figure 2C). Moreover, increased alkaline phosphatase serum levels (P = .01), thrombocytopenia (P = .03), and splenomegaly (P = .04) showed an impact on patients' PFS (Table 4). In turn, the presence of skin lesions (P = .02), thrombocytopenia (P = .04), decreased hemoglobin levels (P = .001), and increased alkaline phosphatase (P = .01) and β2-microglobulin serum levels (P = .04) at diagnosis were all significantly associated with a shorter OS in the univariate analysis (Table 4).

Multivariate analysis of prognostic factors, for the 20 SM patients in whom the somatic vs germline nature of the mutations identified was assessed, including those variables that had a significant impact on patient outcome in the univariate analysis (alkaline phosphatase serum levels and the number of multilineal, somatic, and total [somatic plus germline] mutations, for PFS, and the former variables plus platelet counts and the number of germline genetic variants, for OS), showed that the presence of ≥1 somatic mutation (other than *KIT* D816V) with multilineal hematopoietic involvement was the only independent predictor for PFS (P = .003; hazard ratio [HR], 2.8; 95% confidence interval [CI], 1.4-5.5) and OS (P = .002; HR, 9.3; 95% CI, 2.2-39.2). In turn, multivariate analysis of prognostic factors based on those variables with a significant impact in the univariate analysis that were available in all 34 SM patients studied (ie, alkaline phosphatase serum levels, platelet count, splenomegaly, and presence of *S/A/R* or *S/AR/E* gene mutations, for PFS, and these variables plus skin lesions and hemoglobin and β2-microglobulin serum levels, for OS) showed that the presence of *S/A/R/E* gene mutations (HR, 7.6; 95% CI, 2.2-26; P = .001 for PFS and HR, 13.1; 95% CI, 2.7-64; P = .001 for OS) was the only independent predictor for a worse patient outcome (Table 5).

Discussion

Despite the (potentially) early acquisition of the *KIT* D816V mutation during ontogeny,[12] the onset of clinical symptoms associated with advanced forms of SM often occurs at middle or late adulthood.[5,42] Such observations suggest that continuous activation of the defective (ie, D816V-mutated) SCF/*KIT* pathway in an early progenitor cell does not confer a malignant phenotype per se, whereas it might facilitate malignant transformation of the disease, either because of an increased susceptibility to acquire secondary "oncogenic" mutations and/or by cooperating with a particular (preexisting) genetic background. Thus, results derived from murine models[43,44] and SM patients[13,42,43] indicate that coexistence of different mutations along with *KIT* D816V is required for the development of advanced SM. Hence, recent studies have found higher numbers of additional (somatic) mutations in advanced SM vs ISM patients.[13] Despite these observations, neither additional somatic mutations (apart from *KIT* D816V) nor a specific genetic background have been reported in common among advanced SM cases.[13,16-18,34,43,45-47]

This is the first study in which a large number of genes that might be involved in malignant transformation of nonadvanced to advanced forms of SM have been investigated in a group of SM patients presenting with multilineal *KIT* D816V mutation and high serum tryptase levels. For this purpose, the complete coding regions of 410 genes (including the *SRSF2* p.P95 hotspot) were first analyzed in gDNA from purified BM cell populations from 20 SM patients.

Despite the fact that progression of ISM to more aggressive forms of the disease is a relatively rare event,[2] a high rate of progression was observed within our ISM cases; this high rate of progression could be explained by the patient-selection criteria (advanced SM patients plus nonadvanced ISM cases with high-risk features, such as high serum tryptase levels and multilineal involvement of the hematopoiesis by the *KIT* D816V mutation,[6] including, in the great majority of cases, *KIT* D816V–mutated BM MSCs[12]) and the long follow-up of our cases.

Overall, no common mutation shared among ASM and ISM cases that showed disease progression was found. Hence, except for the



Figure 1. Kaplan-Meier estimates of PFS and OS of SM patients (n = 20) grouped according to the number and type of mutations detected. Panels describe PFS (left panels) and OS (right panels) of patients grouped according to the number of total genetic variants (A), germline genetic variants (B), multilineal somatic mutations (C), and MC restricted (somatic) mutations (D). Values are expressed in years from diagnosis to disease progression (PFS) and death (OS) or the last follow-up visit. Median PFS and/or OS indicates the time point at which half of the patients have progressed to more aggressive forms of the disease or died, respectively.

Table 4. SM patients: prognostic factors for PFS and OS (n = 34)

Disease features	n	Univariate analysis: PFS, y Median (range)	PFS P	Univariate analysis: OS, y Median (range)	OS P
Clinical and laboratory features					
Diagnosis					
Nonadvanced SM	12	14 (2-32)	NS	NR (3-48)	NS
Advanced SM	22	11 (1-18)		11 (1-18)	
Age at diagnosis, y					
<60	23	14 (1-32)	NS	NR (1-48)	NS
≥60	11	5 (1-10)		6 (1-12)	
Skin lesions					
No	10	4 (1-6)	NS	6 (1-13)	0.02
Yes	24	14 (1-32)		NR (3-48)	
BM MCs, %					
<1	14	5 (1-19)	NS	11 (1-19)	NS
≥1	18	14 (1-32)		NR (1-48)	
sBT, μg/L					
<200	10	15 (1-17)	NS	NR (1-17)	NS
≥200	22	6 (1-32)		NR (1-48)	
Hemoglobin, g/L					
<100	5	3 (1-6)	NS	4 (1-7)	.001
≥100	29	14 (1-32)		NR (1-48)	
Platelets, $\times 10^9$/L					
<100	11	4 (1-15)	.03	4 (1-17)	.04
≥100	23	14 (1-32)		NR (1-48)	
β2-microglobulin, μg/mL					
<2.5	7	NR (2-18)	NS	NR (3-17)	.04
≥2.5	20	5 (1-32)		10 (1-48)	
SAP, U/L					
<150	16	32 (2-32)	.01	NR (3-48)	.01
≥150	14	4 (1-30)		10 (1-39)	
Splenomegaly					
No	11	30 (1-30)	.04	NR (1-39)	NS
Yes	23	5 (1-32)		11 (1-48)	
Hepatomegaly					
No	16	15 (1-19)	NS	NR (1-19)	NS
Yes	18	5 (1-32)		11 (1-48)	
Number of nonsynonymous coding genetic variants					
Total somatic mutations					
0	9	30 (2-32)	.02	NR (3-48)	.005
≥1	11	4 (1-15)		6 (2-17)	
MC restricted					
0	15	14 (1-32)	NS	NR (2-48)	NS
≥1	5	6 (1-15)		7 (6-17)	
Multilineal					
0	10	30 (2-32)	.009	NR (3-48)	.001
≥1	10	3 (1-10)		6 (2-10)	

NR, not reached; NS, not statistically significant ($P > .05$); SAP, serum alkaline phosphatase; WT, wild-type.

Table 4. (continued)

Disease features	n	Univariate analysis			
		PFS, y		OS, y	
		Median (range)	*P*	Median (range)	*P*
Germline genetic variants					
<3	17	14 (1-32)	.016	NR (4-48)	.004
≥3	3	3 (1-4)		4 (2-10)	
Total genetic variants					
<3	11	30 (2-32)	.002	NR (3-48)	<.001
≥3	9	3 (1-6)		6 (2-10)	
Gene panel mutational status					
S/A/R					
WT	23	15 (2-32)	<.001	NR (3-48)	.002
Mutated	11	2 (1-4)		6 (1-13)	
S/A/R/E					
WT	19	30 (2-32)	<.001	NR (3-48)	<.001
Mutated	15	3 (1-6)		6 (1-13)	

NR, not reached; NS, not statistically significant ($P > .05$); SAP, serum alkaline phosphatase; WT, wild-type.

IKZF1 p.N159S, *RUNX1* p.R162K, and *SRSF2* p.P95R mutations found in 2 patients each, all other (specific) genetic variants identified were detected in our series in a single case. In line with this as well, only 2 of 67 variants (*SF3B1* p.K666T and *SRSF2* p.P95R mutations) identified in this study had been reported in SM patients.[16] Furthermore, WGS performed in a subset of 4 ASM patients (ie, ASM without an another hematological neoplasm [AHN]), confirmed the absence of common nonsynonymous (coding) genetic variants, other than *KIT* D816V. Interestingly, the mutation rate observed within purified BM clonal MCs in these 4 cases (0.12 per Mb) was significantly lower than that reported for other myeloid neoplasms[48] and other types of cancer.[49] Such a reduced overall mutational rate of ASM cases could be due to the lower genetic/genomic instability of advanced SM compared with other myeloid malignancies; however, despite the fact that the number of BM MCs is typically increased in ASM vs ISM, the most relevant "tumor" cell in advanced SM patients might be hematopoietic precursor cells[10,50] and not pathological BM MCs, because all of these cases had multilineal involvement of the hematopoiesis by *KIT* D816V. If this holds true, neutrophils and, to a lesser extent, T cells would probably share most of the genetic variants found in pathological MCs. In line with this hypothesis, our results confirmed that most (77%) somatic mutations identified in BM MCs were also present in the myeloid or the myeloid plus lymphoid BM cells analyzed.

Surprisingly, half of all genetic variants found in BM MCs were also detected in gDNA from paired hair samples at ~50% allele burden, suggesting that they would correspond to germline genetic events or to mutations acquired early during ontogeny. Interestingly, most patients (70%) carried ≥1 (potentially deleterious) germline genetic event for the 410 genes investigated in this study, which reveals an extremely high frequency compared with the 4% to 30% cases with germline mutations identified in pediatric and adult populations with other types of cancers.[51-53] Despite this, the presence of germline mutations only showed a prognostic impact for PFS and OS when ≥3 germline variants were present in the same patient. However, all 3 cases displaying ≥3 germline variants (patients 18, 19, and 20) also carried a greater number of additional (multilineal) somatic mutations, identifying a potential greater genomic instability among these patients. This might also explain the greater and independent prognostic impact of the number of somatic vs germline mutations among our patients. Despite all of the above, the small number of cases analyzed here and the lack of uniform criteria across different laboratories to label a germline mutation as a deleterious variant,[54] including the use of different filtering criteria for their identification, patients with germline mutations in cancer-related genes are being identified more frequently and, due to their distinct clinical behavior, they now represent a unique subtype of myeloid malignancies in the current WHO classification.[3]

Recently, age-related clonal hematopoiesis (ARCH) has been associated with somatic mutations in genes also found to be altered frequently in myeloid neoplasms (eg, the *ASXL1*, *DNMT3A*, *EZH2*, *RUNX1*, *SF3B1*, *SRSF2*, and *TET2* genes) involving ~10% of otherwise healthy individuals by the age of 70 years.[55,56] Of note, these individuals would have a 12-fold higher relative risk for developing a hematological cancer; therefore, ARCH is considered an age-related preleukemic condition.[57,58] In line with this finding, half of our SM patients who harbored ≥1 ARCH mutation (n = 10/18 cases; 56%) already exhibited an AHN at diagnosis or subsequently developed an AHN in addition to the SM, whereas these mutations affected a smaller percentage of SSM (11%) and ASM (33%) cases. These findings might suggest that acquisition of ARCH-associated gene mutations in ISM patients could be a trigger for a (myeloid) AHN, but not progression to SSM or ASM.

Analysis of the potential sequence of acquisition of somatic mutations in multimutated patients (coexistence of ≥2 somatic mutations) showed a potentially early acquisition of the *KIT* mutation in approximately one third of cases. In another third of our cases, the *KIT* D816V mutation emerged in a distinct clone or later than other multilineal somatic mutations involving, for example, the *TET2*, *RUNX1*, and *EZH2* genes, with most of these patients having or



Figure 2. Kaplan-Meier estimates of PFS and OS of SM patients (n = 34) grouped according to the mutational status of *SRSF2*, *ASXL1*, *RUNX1* and *EZH2* genes. PFS (left panels) and OS (right panels) of SM patients grouped according to the presence vs absence of mutated *S/A/R* genes (A), the *EZH2* mutational status within the *S/A/R* gene panel (B), and the presence vs absence of mutated *S/A/R/E* genes (C). Values are expressed in years from diagnosis to disease progression (PFS) and death (OS) or the last follow-up visit. Median PFS and/or OS indicates the time point at which half of the patients have progressed to more aggressive forms of the disease or died, respectively.

developing SM-AHN. Altogether, these findings support previous observations in (mostly) SM-AHN patients that showed a predominance of gene mutations, other than *KIT* D816V alone or in combination with *KIT* mutations, in (in vitro) expanded colony-forming cells from SM patients.[16] Moreover, in the only case in which we could confirm that the *KIT* mutation was a secondary genetic event, the development of a myeloid proliferative neoplasm occurred just prior to death. The apparent discrepancy between our data and previous data indicating that the *KIT* mutation might frequently occur as a distinct and late event[16] in advanced mastocytosis might be due to the fact that all multimutated patients analyzed in such series (12/12) corresponded to SM-AHN patients[16] with preferential growth of *KIT*

Table 5. SM: multivariate analyses of prognostic factors for PFS and OS for the entire patient series (n = 34)

Disease features	n	PFS HR (95% CI)	PFS *P*	OS HR (95% CI)	OS *P*
Clinical and laboratory features					
Hemoglobin, g/L					
<100	5	NT		NS	
≥100	29				
Skin lesions					
No	10	NT		NS	
Yes	24				
Platelets, $\times 10^9$/L					
<100	11	NS		NS	
≥100	23				
β2-microglobulin, μg/mL					
<2.5	7	NT		NS	
≥2.5	20				
SAP, U/L					
<150	16	NS		NS	
≥150	14				
Splenomegaly					
No	11	NS		NS	
Yes	23				
Gene panel mutational status					
S/A/R					
WT	23	NS		NS	
Mutated	11				
S/A/R/E					
WT	19	7.6 (2.2-2.6)	.001	13.1 (2.7-64)	.001
Mutated	15				

NS, not statistically significant ($P > 0.05$); NT, not tested.

wild-type vs *KIT*-mutated tumor cell precursors, whereas our series was selectively enriched for multilineal *KIT*-mutated ISM and ASM cases. However, clonogenic assays and/or single-cell analyses have not been performed in this study; therefore, our conclusions should be viewed with caution.

Interestingly, among our cases, most genes targeted by acquired somatic mutations, other than *KIT* D816V (ie, *ASLXL1*, *DNMT3A*, *EZH2*, *IKZF*1, *RUNX1*, *SF3B1*, *SRSF2*, *TET2*), had previously been found to be mutated in advanced SM[13,16,17,34,46,47] and/or in other myeloid neoplasias,[19,21,45,55,59-62] and their multilineal nature was shown in this study for the first time. In addition, the number of mutated genes (apart from *KIT*) with multilineal involvement of hematopoiesis increased significantly from ISM to ASM cases, in line with previous observations.[17] Altogether, these findings further support the role of the *KIT* D816V mutation as a trigger for advanced SM under a "dangerous" genetic background, defined not only by the (number of) preexisting germline variants, as well as by the presence of (previously) acquired multilineal mutations in genes other than *KIT*. Actually, the presence of ≥1 somatic mutation with multilineal hematopoietic involvement, in addition to *KIT*, or the presence of ≥3 nonsynonymous coding genetic variants (including somatic and germline events) in the genes investigated in this study significantly increased the probability of progression of SM and of shortening the OS of SM patients.[19,20,60]

To explore the potential clinical utility of NGS screening based on a reduced number of genes, we investigated the prognostic impact of the previously reported (adverse) *S/A/R* gene panel[17] in our patients. Our results confirmed that patients carrying ≥1 mutation in *S/A/R* genes had significantly poorer PFS and OS.[17] However, inclusion of *EZH2* into a *S/A/R/E* gene panel revealed that the combination of mutations in these 4 genes had greater predictive value for PFS and OS than did the well-established *S/A/R* gene panel, because *S/A/R/E* gene mutations were shown to be the only independent predictor for PFS and OS in our SM patients. Of note, *EZH2* was 1 of the most frequently mutated genes in our series and 1 of the most frequently mutated genes in other cohorts of patients with SM[13,16] and other myeloid neoplasms,[19,20,63] where its mutations emerged as never being shared with *SRSF2* mutations[64,65]; this might contribute to explain its additional prognostic information over the *S/A/R* gene mutations. This observation differs from data reported by other investigators[17,62] who also tested the influence of mutations in the *EZH2* gene; however, both studies[17,62] included a significantly shorter median patient follow-up than ours (eg, 3.6 and 2 years vs 6.5 years, respectively), a period during which less than half of our ISM patients who progressed would have transformed to SSM and other forms of advanced SM. Thus, further investigations in larger series of SM patients, with a long follow-up, are required to confirm these findings.

In summary, our results show that no individual genetic lesion apart from the (multilineal) KIT mutation appears to be an independent predictor for malignant transformation of SM; however, progression of ISM to more advanced forms of the disease most likely requires an altered multimutated genetic background of both (KIT-mutated) tumor MCs and other hematopoietic BM cells. Germline and multilineal somatic mutations (particularly those involving the SRSF2, ASXL1, and RUNX1 genes in addition to the EZH2 gene) emerge as critical genetic markers associated with disease progression and a shortened OS for ISM patients at higher risk of disease progression.

Acknowledgments

The authors thank the Cell Sorting Service and Spanish National DNA Bank Carlos III (NUCLEUS, University of Salamanca) for technical assistance.

This work was supported by grants from the Instituto de Salud Carlos III (ISCIII) and fondos FEDER (PI16/00642 and CIBERONC [CB16/12/00400]), Madrid, Spain; Consejería de Educación, Junta de Castilla y León (SA013U16, FEDER), Valladolid, Spain; and Fundación Ramón Areces (CIVP16A1806), Madrid, Spain. M.J.-A. was supported by Ministerio de Economia y Competitividad (PTA-2016)–Universidad de Salamanca. A. Mayado was supported by CIBERONC (CB16/12/00400). J.I.S.-G. was supported by Consejería de Educación, Junta de Castilla y León (SA013U16), and FEDER. Spanish National DNA Bank Carlos III was supported by ISCIII and fondos FEDER (PT13/0001/0037 and PT17/0015/0044).

Authorship

Contribution: J.I.M.-G. performed experiments, analyzed data, and wrote the manuscript; M.J.-A., I.A.-T., and C.T. helped with the statistical analysis, the data analysis, and the review of the manuscript;

C.C. and A. Mayado helped with data analysis and reviewed the manuscript; Y.H., K.M.R., and A.G.T. analyzed data and reviewed the manuscript; A.H. provided patient clinical data and reviewed the manuscript; L.S.-M., A. Matito, J.I.S.-G., and N.D.-F. reviewed the manuscript; and J.D.M., J.R.G., L.E., A.O., and A.C.G.-M. designed the experiments, analyzed the data, and wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: J.I.M.-G., 0000-0001-8982-5663; N.D.-F., 0000-0002-9633-1749; A.O., 0000-0002-0007-7230; A.C.G.-M., 0000-0003-4360-1386.

Correspondence: Alberto Orfao, Centro de Investigación del Cáncer, Campus Miguel de Unamuno, 37007 Salamanca, Spain; e-mail: orfao@usal.es; and Andrés C. García-Montero, Centro de Investigación del Cáncer, Campus Miguel de Unamuno, 37007 Salamanca, Spain; e-mail: angarmon@usal.es.

References

1. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. *Leuk Res*. 2001;25(7):603-625.
2. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. *Blood*. 2017;129(11):1420-1427.
3. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016;127(20):2391-2405.
4. Akin C. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. *J Mol Diagn*. 2006;8(4):412-419.
5. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. *Blood*. 2009;113(23):5727-5736.
6. Escribano L, Alvarez-Twose I, Sánchez-Muñoz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. *J Allergy Clin Immunol*. 2009;124(3):514-521.
7. Pardanani A, Lim KH, Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. *Blood*. 2009;114(18):3769-3772.
8. Longley BJ Jr, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. *Proc Natl Acad Sci USA*. 1999;96(4):1609-1614.
9. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L; REMA. Recent advances in the understanding of mastocytosis: the role of KIT mutations. *Br J Haematol*. 2007;138(1):12-30.
10. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. *Blood*. 2006;108(7):2366-2372.
11. Sotlar K, Colak S, Bache A, et al. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). *J Pathol*. 2010;220(5):586-595.
12. Garcia-Montero AC, Jara-Acevedo M, Alvarez-Twose I, et al. KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression. *Blood*. 2016;127(6):761-768.
13. Schwaab J, Schnittger S, Sotlar K, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. *Blood*. 2013;122(14):2460-2466.
14. Bibi S, Langenfeld F, Jeanningros S, et al. Molecular defects in mastocytosis: KIT and beyond KIT. *Immunol Allergy Clin North Am*. 2014;34(2):239-262.
15. Wilson TM, Maric I, Simakova O, et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. *Haematologica*. 2011;96(3):459-463.
16. Jawhar M, Schwaab J, Schnittger S, et al. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. *Leukemia*. 2015;29(5):1115-1122.
17. Jawhar M, Schwaab J, Schnittger S, et al. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. *Leukemia*. 2016;30(1):136-143.
18. Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. *Leukemia*. 2009;23(5):900-904.
19. Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. *J Clin Oncol*. 2012;30(27):3376-3382.
20. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. *N Engl J Med*. 2011;364(26):2496-2506.
21. Kar SA, Jankowska A, Makishima H, et al. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. *Haematologica*. 2013;98(1):107-113.
22. Tzankov A, Sotlar K, Muhlematter D, et al. Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3. *J Clin Pathol*. 2008;61(8):958-961.
23. Wang SA, Hutchinson L, Tang G, et al. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. *Am J Hematol*. 2013;88(3):219-224.
24. van Dongen JJM, Lhermitte L, Böttcher S, et al; EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. *Leukemia*. 2012;26(9):1908-1975.

25. Muñiz C, Teodosio C, Mayado A, et al. Ex vivo identification and characterization of a population of CD13(high) CD105(+) CD45(−) mesenchymal stem cells in human bone marrow. *Stem Cell Res Ther*. 2015;6(1):169.

26. Kristensen T, Vestergaard H, Møller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. *J Mol Diagn*. 2011;13(2):180-188.

27. Jara-Acevedo M, Teodosio C, Sanchez-Muñoz L, et al. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. *Mod Pathol*. 2015;28(8):1138-1149.

28. Lander ES, Linton LM, Birren B, et al; International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome [published correction appears in *Nature* 2001;411(6838):720 and *Nature* 2001;412(6846):565]. *Nature*. 2001;409(6822):860-921.

29. Fu W, O'Connor TD, Jun G, et al; NHLBI Exome Sequencing Project. Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants [published correction appears in *Nature* 2013;495(7440):270]. *Nature*. 2013;493(7431):216-220.

30. Auton A, Brooks LD, Durbin RM, et al; 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature*. 2015;526(7571):68-74.

31. Lek M, Karczewski KJ, Minikel EV, et al; Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. *Nature*. 2016; 536(7616):285-291.

32. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. *Nucleic Acids Res*. 2003;31(13):3812-3814.

33. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. *Nat Methods*. 2010;7(4):248-249.

34. Hanssens K, Brenet F, Agopian J, et al. SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes. *Haematologica*. 2014;99(5):830-835.

35. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet*. 2011; 43(5):491-498.

36. Li H, Handsaker B, Wysoker A, et al; 1000 Genome Project Data Processing Subgroup. The sequence alignment/map format and SAMtools. *Bioinformatics*. 2009;25(16):2078-2079.

37. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics*. 2010;26(6):841-842.

38. Hsu F, Kent WJ, Clawson H, Kuhn RM, Diekhans M, Haussler D. The UCSC known genes. *Bioinformatics*. 2006;22(9):1036-1046.

39. Karolchik D, Hinrichs AS, Furey TS, et al. The UCSC Table Browser data retrieval tool. *Nucleic Acids Res*. 2004;32(Database issue):D493-D496.

40. Bouliotis G, Billingham L. Crossing survival curves: alternatives to the log-rank test. *Trials*. 2011;12(suppl 1):A137.

41. Delgado J, Pereira A, Villamor N, López-Guillermo A, Rozman C. Survival analysis in hematologic malignancies: recommendations for clinicians. *Haematologica*. 2014;99(9):1410-1420.

42. Broesby-Olsen S, Kristensen TK, Møller MB, Bindslev-Jensen C, Vestergaard H; Mastocytosis Centre, Odense University Hospital (MastOUH). Adult-onset systemic mastocytosis in monozygotic twins with KIT D816V and JAK2 V617F mutations. *J Allergy Clin Immunol*. 2012;130(3):806-808.

43. Soucie E, Hanssens K, Mercher T, et al. In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. *Blood*. 2012;120(24):4846-4849.

44. De Vita S, Schneider RK, Garcia M, et al. Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. *PLoS One*. 2014;9(5):e96209.

45. Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. *Leukemia*. 2011;25(7):1153-1158.

46. Damaj G, Joris M, Chandesris O, et al. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. *PLoS One*. 2014;9(1):e85362.

47. Traina F, Visconte V, Jankowska AM, et al. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. *PLoS One*. 2012;7(8):e43090.

48. Ley TJ, Miller C, Ding L, et al; Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med*. 2013;368(22):2059-2074.

49. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature*. 2013;499(7457): 214-218.

50. Akin C, Kirshenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. *Exp Hematol*. 2000;28(2):140-147.

51. Zhang J, Walsh MF, Wu G, et al. Germline mutations in predisposition genes in pediatric cancer. *N Engl J Med*. 2015;373(24):2336-2346.

52. Walsh M, Wu G, Edmonson M, et al. Incidence of germline mutations in cancer-predisposition genes in children with hematologic malignancies: a report from the Pediatric Cancer Genome Project. *Blood*. 2014;124(21):127.

53. Furutani E, Shimamura A. Germline genetic predisposition to hematologic malignancy. *J Clin Oncol*. 2017;35(9):1018-1028.

54. Kohlmann W, Schiffman JD. Discussing and managing hematologic germ line variants. *Blood*. 2016;128(21):2497-2503.

55. Mason CC, Khorashad JS, Tantravahi SK, et al. Age-related mutations and chronic myelomonocytic leukemia. *Leukemia*. 2016;30(4):906-913.

56. Hirsch CM, Przychodzen BP, Radivoyevitch T, et al. Molecular features of early onset adult myelodysplastic syndrome. *Haematologica*. 2017;102(6): 1028-1034.

57. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. *N Engl J Med*. 2014; 371(26):2477-2487.

58. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med*. 2014;371(26):2488-2498.
59. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. *Leukemia*. 2010;24(6):1128-1138.
60. Papaemmanuil E, Gerstung M, Malcovati L, et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. *Blood*. 2013;122(22):3616-3627, quiz 3699.
61. Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. *Blood*. 2012;119(15):3578-3584.
62. Pardanani A, Lasho T, Elala Y, et al. Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival. *Am J Hematol*. 2016;91(9):888-893.
63. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. *Leukemia*. 2013;27(9):1861-1869.
64. Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). *Blood*. 2012;120(15):3080-3088.
65. Bejar R. Splicing factor mutations in cancer. *Adv Exp Med Biol*. 2016;907:215-228.

Supplemental Text

METHODS

DNA extraction and molecular studies. gDNA was extracted from highly-purified BM cell populations using either the GenElute Mammalian Genomic DNA Miniprep (Sigma-Aldrich, St Louis, MO) or the NucleoSpin Tissue XS kits (Macherey-Nagel, Düren, Germany) for samples containing >100,000 cells and <100,000 cells, respectively. Peripheral blood (PB) gDNA was extracted by the salting-out method (Gentra Puregene Blood kit; Qiagen, Hilden, Germany), following the standard operating procedures of the Spanish National DNA Bank Carlos III (University of Salamanca, Salamanca, Spain; http://www.bancoadn.org). In turn, gDNA from hair was extracted using the micro-DNA Qiagen kit (QIAGEN, Valencia, CA) after discarding hair follicles. For the *KIT* D816V real-time allele-specific oligonucleotide PCR (ASO-qPCR)[1] assay, both the LightCycler thermocycler and the TaqMan Master Kit (Roche Diagnostics, Mannheim, Germany) were used.

Identification of BM cell populations. BM MC were identified as $CD117^{hi}CD45^{+}CD34^{-}CD3^{-}CD14^{-}$, maturing neutrophils as $CD45^{+}CD34^{-}CD117^{-}CD3^{-}CD14^{-}SSCA^{hi}$ cells, mesenchymal stem cells as $CD105^{+}CD13^{hi}CD45^{-}CD34^{-}CD14^{-}CD3^{-}$ and T lymphocytes corresponded to $CD3^{+}CD45^{+}CD34^{-}CD14^{-}CD117^{-}$ cellular events

Whole genome sequencing analysis. Single nucleotide and indel variants were called using MuTect2[2] (version 3.6) to identify variants present in MC while absent or present at a very low levels in T-cells. Variants identified were manually inspected if: 1) allele

frequency ≥20%, and 2) a non-synonymous coding change was identified or they involved the invariant 2 bases of the donor or acceptor splice site. Integrative Genomics Viewer (version 2.3.81) was used to review the read sequence, base quality scores, and mapping scores across all 4 MC/T-lymphocyte pairs. The genomic context of the variant regions was further examined using the UCSC Genome Browser (hg19) (http://genome.ucsc.edu/). Features that were used to exclude potential somatic variants for further consideration, included: 1) < 3 variant reads in the neoplastic specimen, 2) variant reads that matched a region of the genome with ≥1 highly homologous regions, 3) equivalent percentages of mutant reads observed in MC and T-lymphocytes, and 4) common SNPs (MAF ≥0.01 that uniquely map with no "clinically associated" flag). All variants that passed the manual inspection were confirmed by Sanger sequencing. Reported mutant and total read counts, were calculated based on alt and ref read counts provided by MuTect2, and the mutated allele burden was calculated from these values.

Due to the low mutation burden, variants were filtered further to improve specificity and better calculate the somatic mutation load. The number of reads supporting a single nucleotide variant (SNV) in the normal samples was calculated using bam-readcount[3] (version 0.7.4). SNV were filtered to remove variants with any of the following features: 1) <3 supporting reads in tumor MC; 2) >2 supporting reads in any of the T-cell specimens; 3) allele frequency <20%. All MC-restricted SNVs for patient #9 were manually reviewed. Since the number of SNV calls in patients #10, #13, and #14 were >250, 25 randomly selected SNVs from each of these three cases (n=75), were manually reviewed and 90.7% passed the manual inspection. Similarly, indel variants were filtered to remove variants with any of the following: 1) <3 supporting reads; 2) allele frequency <20%; 3) indels included in or within 10 bp of the RepeatMasker regions (table rmsk, downloaded Dec. 12, 2016 from the UCSC Table

Browser)[4,5]; 4) indels included in a segmental duplication (table genomicSuperDups, downloaded Dec. 19, 2016 from the UCSC Table Browser[4]); 5) indels included in a region with mappability = 0 in the "Duke Uniqueness 20 bp Track" (table wgEncodeDukeMapabilityUniqueness20bp, downloaded Dec. 19, 2016 from the UCSC Table Browser)[4,6]. To evaluate the resulting MC-restricted indels, we manually curated all indels from each of the cases.

1. Kristensen T, Vestergaard H, Moller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. *J Mol Diagn*. 2011;13(2):180-188.
2. https://software.broadinstitute.org/gatk/blog?tag=mutect2 M.
3. https://github.com/genome/bam-readcount b-r.
4. Karolchik D, Hinrichs AS, Furey TS, et al. The UCSC Table Browser data retrieval tool. *Nucleic Acids Res*. 2004;32(Database issue):493-496.
5. Smit AFA HR, Green P. RepeatMasker Open-3.0. http://www.repeatmasker.org. 1996-2010.
6. Derrien T, Estelle J, Marco Sola S, et al. Fast computation and applications of genome mappability. *PLoS One*. 2012;7(1):303-377.

Supplemental Table S-1.- Immunophenotypic markers used for the identification and isolation of bone marrow neutrophils, mast cells, monocytes and T cells.

MARKER	ANTIBODY CLONE	FLUOROCHROME CONJUGATE	MANUFACTURER
CD3	UCHT1	PacB	BD Bioscience
CD13	WM15/L138	APC/PE	Beckman Coulter
CD14	MφP9	APC-H7	BD Bioscience
CD34	8G12	PerCPCy5.5 / APC	BD Bioscience
CD45	HI30	PacO	Invitrogen
CD105	166707/1G2	FITC/PE	R&D Systems/ Beckman Coulter
CD117	104D2D1	PECy7	BeckmanCoulter
MSCA-1	W8B2	PE	Miltenyi Biotec

APC, allophycocyanine; Cy7, cyanine7; FITC, fluorescein isothiocyanate; H7, Hilite7; PacB, pacific blue; PE, phycoerythrin; PerCPCy5.5, peridinin chlorophyll protein–cyanine5.5; PacO, pacific orange. BD Biosciences, San Diego, CA; Invitrogen, Carlsabad, CA; Beckman Coulter, Hialeah, FL; R&D Systems, Minneapolis, MN; Miltenyi Biotec, Bergisch Gladbach, Germany.

Supplemental Table S-2.- List and type of mutations found in SM patients (n=20) according to the pattern of involvement of the different BM cell compartments analyzed and hair, and their corresponding allele burden.

Patient ID	Pattern of cell lineages involved by the mutation				Amino acid changes	Reference sequence transcript ID	BM MC Mutated allele burden	BM neutrophils Mutated allele burden	Literature citations	COSMIC ID
	MC-Restricted	Multiple myeloid lineages	Myeloid plus lymphoid lineages	Germline genetic variants or early acquired mutations						
#1			*KIT*		p.D816V	NM_000222.2	45%	NA	854	COSM1314
#2				*EP400*	p.V2955I	NM_015409.4	50%	NA	-	
#2			*KIT*		p.D816V	NM_000222.2	45%	NA	854	COSM1314
#3			*KIT*		p.D816V	NM_000222.2	41%	NA	854	COSM1314
#3				*RECQL4*	p.N616S	NM_004260.3	49%	NA	-	
#3				*NSD2*	p.Q295L	NM_133330.2	53%	NA	-	
#4				*DCC*	p.R211L	NM_005215.3	52%	NA	-	
#4			*KIT*		p.D816V	NM_000222.2	46%	NA	854	COSM1314
#5	*ITGA10*				p.F420L	NM_003637.3	32%	NA	-	
#5			*KIT*		p.D816V	NM_000222.2	47%	NA	854	COSM1314
#6			*KIT*		p.D816V	NM_000222.2	51%	NA	854	COSM1314
#7				*CSF1R*	p.N255I	NM_005211.3	51%	NA	1	COSM5019188
#7			*KIT*		p.D816V	NM_000222.2	24%	NA	854	COSM1314
#7				*MARK4*	p.G374C	NM_031417.3	54%	NA	-	
#7		*RUNX1*			p.N146K	NM_001754.4	50%	NA	-	
#8			*KIT*		p.D816V	NM_000222.2	42%	14%	854	COSM1314
#8				*SYNE1*	p.R7753H	NM_182961.3	47%	47%	2	COSM1074697
#9				*IGF2R*	p.S828L	NM_000876.2	54%	NA	-	
#9				*ITPKA*	p.R741W	NM_002344.5	46%	NA	-	
#9			*KIT*		p.D816V	NM_000222.2	47%	NA	854	COSM1314
#10				*HSP90AA1*	p.T274A	NM_001017963.2	48%	51%	-	
#10			*KIT*		p.D816V	NM_000222.2	38%	14%	854	COSM1314
#11			*DNMT3A*		p.R882C	NM_022552.4	50%	NA	192	COSM53042
#11	*EZH2*				p.R583Q	NM_004456.4	40%	NA	-	
#11			*KIT*		p.D816V	NM_000222.2	49%	NA	854	COSM1314
#11	*SF3B1*				p.K700E	NM_012433.2	46%	NA	465	COSM84677
#12		*ASXL1*			p.*1542fs	NM_015338.5	63%	50%	1	COSM914371
#12				*DCC*	p.P1353L	NM_005215.3	50%	53%	-	
#12			*DNMT3A*		p.R882H	NM_022552.4	62%	50%	459	COSM52944
#12	*IKZF1*				p.N159S	NM_006060.4	38%	0%	-	
#12			*KIT*		p.D816V	NM_000222.2	46%	16%	854	COSM1314
#13			*KIT*		p.D816V	NM_000222.2	44%	15%	854	COSM1314
#13				*SDHC*	p.A3E	NM_003001.3	50%	49%	-	

Supplemental Table S-2.- List and type of mutations found in SM patients (n=20) according to the pattern of involvement of the different BM cell compartments, analyzed and hair, and their corresponding allele burden. (Continued)

Patient ID	Pattern of cell lineages involved by the mutation				Amino acid changes	Reference sequence transcript ID	BM MC Mutated allele burden	BM neutrophils Mutated allele burden	Literature citations	COSMIC ID
	MC-Restricted	Multiple myeloid lineages	Myeloid plus lymphoid lineages	Germline genetic variants or early acquired mutations						
#14			*EPHA7*		p.Q809R	NM_004440.3	37%	NA	1	COSM4649765
#14			*KIT*		p.D816V	NM_000222.2	52%	NA	854	COSM1314
#14	*PIK3CD*				p.L598P	NM_005026.3	37%	NA	-	
#15				*DST*	p.Y8T	NM_015548.4	48%	NA	-	
#15		*EZH2*			p.L50W	NM_004456.4	44%	NA	-	
#15		*IKZF1*			p.N159S	NM_006060.4	46%	NA	-	
#15		*KIT*			p.D816V	NM_000222.2	51%	NA	854	COSM1314
#16				*CREBBP*	p.P153L	NM_004380.2	49%	52%	-	
#16		*KIT*			p.D816V	NM_000222.2	37%	1%	854	COSM1314
#16		*SRSF2*			p.P95R	NM_003016	NA	NA	95	COSM211661
#16		*TET2*			p.N275I	NM_017628.4	50%	53%	-	
#17		*ASXL1*			p.R693*	NM_015338.5	45%	NA	20	COSM132980
#17	*KAT6B*				p.E1360del	NM_012330.3	35%	NA	-	
#17			*KIT*		p.D816V	NM_000222.2	47%	NA	854	COSM1314
#17		*RUNX1*			p.V238fs	NM_001754.4	45%	NA	1	COSM24772
#18				*EPHB6*	p.F716S	NM_004445.4	69%	48%	-	
#18		*EZH2*			p.N608K	NM_004456.4	45%	49%	-	
#18			*KIT*		p.D816V	NM_000222.2	48%	46%	854	COSM1314
#18				*LRP1B*	p.R3239C	NM_018557.2	47%	43%	-	
#18		*ROS1*			p.N2333K	NM_002944.2	51%	48%	-	
#18				*RPS6KA2*	p.G487fs	NM_001006932.1	49%	51%	-	
#18		*SF3B1*			p.K666T	NM_012433.2	50%	46%	20	COSM131556
#19				*CYP2C19*	p.D360E	NM_000769.1	47%	48%	1	COSM3441969
#19		*EZH2*			p.I146T	NM_004456.4	30%	48%	-	
#19			*KIT*		p.D816V	NM_000222.2	8%	5%	854	COSM1314
#19				*LRP1B*	p.G4423D	NM_018557.2	54%	49%	-	
#19				*TCF3*	p.S72C	NM_001136139.2	48%	52%	-	

Supplemental Table S-2.- List and type of mutations found in SM patients (n=20) according to the pattern of involvement of the different BM cell compartments, analyzed and hair, and their corresponding allele burden. (Continued)

Patient ID	Pattern of cell lineages involved by the mutation				Amino acid changes	Reference sequence transcript ID	BM MC Mutated allele burden	BM neutrophils Mutated allele burden	Literature citations	COSMIC ID
	MC-Restricted	Multiple myeloid lineages	Myeloid plus lymphoid lineages	Germline genetic variants or early acquired mutations						
#20				*ADGRB3*	p.S757L	NM_001704.2	43%	45%	-	
#20		*CDH11*			p.P169L	NM_001797.2	25%	35%	2	COSM4796098
#20		*ICK*			p.G16S	NM_014920.3	29%	36%	-	
#20			*KIT*		p.D816V	NM_000222.2	20%	13%	854	COSM1314
#20				*MBD1*	p.E302Q	NM_002384.2	53%	53%	-	
#20				*MUC1*	p.A180T	NM_002456.5	52%	53%	-	
#20				*NFKB2*	p.R658W	NM_001077494.3	47%	48%	1	COSM914184
#20				*NOTCH4*	p.R157W	NM_004557.3	49%	49%	1	COSM3872974
#20		*SRSF2*			p.P95R	NM_003016	NA	NA	95	COSM211661
#20		*RUNX1*			p.N109T	NM_001754.4	25%	13%	-	
#20				*SOCS1*	p.R181C	NM_003745.1	35%	46%	2	COSM4170731
#20		*TET2*			p.E368*	NM_017628.4	91%	97%	1	COSM41898

Mutated allele burden in BM MC and neutrophil cell populations expressed as percentage of total genetic sequence reads. Literature citations represent the number of times those mutations have been cited, according to the COSMIC database (v85, released 08-MAY-18); del, deletion; fs, frameshift mutation; ID, patient code number used to identify patients analyzed in this study; NA, not available; -, not yet registered in the COSMIC database; *, stop codon.

Supplemental Table S-3.- List of mutations found in the second cohort of 14 advanced SM patients included in this study and their corresponding allele burden.

Patient ID	Gene	Amino acid change	Reference sequence transcript ID	BM allele burden	Literature citations	COSMIC ID
#21	*SF3B1*	p.K666T	NM_012433	15%	32	COSM131556
#23	*RUNX1*	p.R166Q	NM_001754	40%	19	COSM36055
#24	*RUNX1*	p.R162K	NM_001754	88%	21	COSM96546
#25	*TET2*	p.H192Y	NM_001127208	44%	-	
#25	*ASXL1*	p.I641fs	NM_015338	49%	3	COSM6017849
#28	*KAT6B*	p.C1704F	NM_012330	55%	-	
#28	*DNMT3A*	p.N879D	NM_175629	28%	4	COSM1583135
#28	*RUNX1*	p.R162K	NM_001754	90%	21	COSM96546
#29	*SRSF2*	p.P95R	NM_003016	43%	105	COSM211661
#29	*RUNX1*	p.A142T	NM_001754	40%	-	
#30	*SRSF2*	p.P95A	NM_003016	43%	6	COSM307352
#31	*RUNX1*	p.R107C	NM_001754	29%	17	COSM24736
#32	*RUNX1*	p.P86fs	NM_001754	54%	-	
#32	*EZH2*	p.Q545X	NM_004456	81%	1	COSM3366844
#33	*ROS1*	p.S252A	NM_002944	52%	-	

Mutated allele burden in BM expressed as percentage of total genetic sequence reads. Literature citations represent the number of times those mutations have been cited, according to the COSMIC database (v85, released 08-MAY-18); ASM, aggressive systemic mastocytosis; fs, frameshift mutation; ID, patient code number used to identify patients analyzed in this study; NA, not available; ID, patient code number used to identify patients analyzed in this study; SM-AHN, systemic mastocytosis associated with another neoplasm; -, not yet registered in the COSMIC database.

Supplemental Table S-4.- Whole genome and targeted sequencing metrics for each SM patient analyzed from the first cohort (n=20)

Patient ID	Purified BM cell population analyzed	Gross mapping yield (Gb)*	Average coverage (total reads)	% Genome with coverage ≥20 reads	% Exome with coverage ≥20 reads
#1	BM mast cells		45.3		100
#2	BM mast cells		47.1		100
#3	BM mast cells		48.6		100
#4	BM mast cells		48.9		100
#5	BM mast cells		39.5		100
#6	BM mast cells		50.8		100
#7	BM mast cells		45.9		100
#8	BM mast cells		44.8		100
#9	BM mast cells		48.8		100
	BM mast cells	119.7	41.9	97.8	97.0
	BM T lymphocytes	146.6	51.3	98.8	98.7
#10	BM mast cells		45.7		100
	BM mast cells	124.1	43.4	97.5	97.3
	BM T lymphocytes	151.4	53.0	99.0	97.9
#11	BM mast cells		47.0		100
#12	BM mast cells		51.4		100
#13	BM mast cells		48.9		100
	BM mast cells	124.8	43.7	97.5	95.3
	BM T lymphocytes	148.1	51.8	98.9	98.7
#14	BM mast cells		42.0		100
	BM mast cells	154.2	53.9	98.8	98.4
	BM T lymphocytes	137.7	48.2	98.6	98.6
#15	BM mast cells		46.7		100
#16	BM mast cells		47.0		100
#17	BM mast cells		51.0		100
#18	BM mast cells		51.2		100
#19	BM mast cells		41.7		83.3
#20	BM mast cells		42.6		100

*Gross mapping yield and other genome sequencing metrics were calculated after removal of duplicate reads. BM, bone marrow; Gb, gigabytes; ID, patient code number used to identify patients analyzed in this study.

Supplemental Table S-5.- Non-synonymous coding and splice site genetic variants restricted to MC as identified by whole genome sequencing performed in a subset of four SM patients.

Patient ID	Gene name	Reference sequence transcript ID	Nucleotide change	Amino acid change	BM MC Mutated allele burden (mutant/total reads)	Literature citations	COSMIC ID
#9	-	-	-	-	-	-	-
#10	*MMS22L*	NM_198468.2	c.268A>G	p.R90G	56% (30/54)	-	-
	COG4	NM_015386.2	c.1252C>A	p.Q418K	46% (18/39)	-	-
	ANKRD12	NM_015208.4	c.3247A>C	p.M1083L	39% (14/36)	-	-
	ZNF544	NM_014480.3	c.1718A>G	p.E573G	32% (12/38)	-	-
#13	*ERBB4*	NM_005235.2	c.2203-1G>A	splice variant	39% (17/44)	1	COSM5608619
	PFAS	NM_012393.2	c.337C>A	p.L113M	41% (13/32)	-	-
	HIRA	NM_003325.3	c.2848G>C	p.G950R	31% (8/26)	-	-
#14	*PIK3CD*	NM_005026.3	c.1721T>C	p.L574P	33% (18/54)	-	-
	NCSTN	NM_015331.2	c.967C>A	p.R323S	56% (28/50)	-	-
	RBMX	NM_002139.3	c.1072C>G	p.P358A	21% (9/43)	-	-

Mutated allele burden in purified BM MC expressed as percentage of total genetic sequence reads. Literature citations represents the number of times those mutations have been cited, according to the COSMIC database (v85, released 08-MAY-18); ID, patient code number used to identify patients analyzed in this study; -, not yet registered in the COSMIC database.

Supplemental Table S-6.- Clinical and laboratory features of SM patients at last follow-up.

Patient ID	Leukocytes (x10^9/L)	Cytopenia	Monocytes (x10^9/L)	Neutrophils (x10^9/L)	Eosinophils (x10^9/L)	Hemoglobin (g/L)	Platelets (x10^9/L)	LDH (U/L)	SAP (U/L)	Albumin (g/L)	Splenomegaly	Hepatomegaly
#1	4.5	NO	0.4	1.8	0.1	118	134	230	<150	>35	NO	NO
#2	14.4	NO	0.9	7.8	1.1	141	350	260	<150	>35	NO	NO
#3	7.1	NO	0.4	5	0.2	148	170	159	<150	>35	NO	NO
Subtotal	7.1 (4.5-14.4)		0.4 (0.4-0.9)	5 (1.8-7.8)	0.2 (0.1-1.1)	141 (118-148)	170 (134-350)	230 (159-260)				
#4	9	NO	0.6	5.4	0.7	144	291	208	<150	>35	YES	NO
#5	2.9	NO	0.2	2.3	0.1	120	100	286	<150	>35	YES	NO
#6	4.6	NO	0.2	3	0.1	123	113	200	<150	>35	YES	YES
#7	8.8	YES	2.5	0.6	0.7	139	130	289	>150	>35	YES	YES
#8	8.1	NO	0.74	2.8	0.1	116	451	114	>150	>35	YES*	YES*
#9	3.4	NO	0.4	4.2	0.1	115	292	130	<150	>35	YES*	YES*
#10	2.6	YES	0.1	2	0.1	132	206	208	>150	>35	NO	YES*
#11	4	YES	0.3	2.7	0.1	94	107	196	>150	NA	NO	YES*
#12	1.2	YES	0.2	0.8	0.1	102	50	314	>150	NA	YES*	NO
#13	9.1	NO	0.5	4.4	1.4	126	321	472	<150	<35	NO	YES
#14	6.7	NO	0.3	4.4	0.5	134	126	221	<150	>35	YES	YES*
#15	16.4	NO	0.8	11.5	0.1	98	40	NA	<150	<35	YES*	NO
#16	13.3	NO	2.1	8.1	1.3	148	20	361	>150	<35	YES*	YES
#17	22.7	NO	3.1	11.1	3.4	101	130	374	196	>35	YES	YES
#18	20.5	NO	0.6	6.8	0.3	86	60	214	>150	>35	YES	YES
#19	3.2	NO	4	NA	NA	104	133	200	>150	>35	YES*	NO
#20	5.3	YES	0.3	1.6	0.4	107	61	407	>150	<35	YES*	YES*
#21	3.3	YES	0.3	2.1	0.1	115	252	219	<150	<35	NO	NO
#22	6.9	NO	0.2	4.6	0.1	139	319	173	<150	<35	NO	NO
#23	4.2	YES	0.2	0.3	0.2	101	16	369	>150	<35	YES	YES
#24	3.2	NO	0.2	2.5	0.3	147	185	310	<150	<35	YES*	NO
#25	3.1	NO	0.2	2.1	0.2	146	142	270	>150	<35	YES	YES
#26	5.7	YES	0.2	1.1	0.1	97	26	454	>150	>35	YES	YES
#27	5	YES	0.4	3.5	0.1	126	35	263	<150	>35	YES	YES
#28	11.7	NO	1.4	3	0.2	136	135	458	>150	>35	YES	YES
#29	1.6	YES	0.03	0.6	0.1	88	204	257	<150	<35	YES	NO
#30	3.3	YES	0.5	1.2	0.2	144	225	197	<150	<35	NO	NO
#31	3.9	NO	0.4	2.6	0.1	142	185	234	<150	<35	YES	NO
#32	5.5	NO	0.4	3.2	0.4	132	298	198	>150	>35	YES	YES
#33	2.5	NO	0.1	2	0.1	115	146	201	<150	<35	YES	YES
#34	4.4	NO	0.2	2.6	0.1	143	164	194	<150	<35	YES	NO
Subtotal	4.4 (1.2-22.7)		0.3 (0.03-4)	2.6 (0.3-11.5)	0.2 (0.1-3.4)	123 (86-148)	133 (16-451)	221 (114-472)				
Total	4.7 (1.2-22.7)		0.4 (0.03-4)	2,7 (0.3-11.5)	0.2 (0.08-3.4)	125 (86-148)	134.5 (16-451)	225.5 (114-472)				

Results expressed as median (range). Abbreviations: **ID**, patient code number used to identify patients analyzed in this study; **LDH,** lactate dehydrogenase; **NA**, not available; **SAP,** serum alkaline phosphatase; ***,** with organ failure.

Supplemental Table S-7.- Cytoreductive treatment received and response of the SM patients at last follow-up.

Patient ID	Indication for cytoreductive therapy	Cytoreductive treatment	Response	Adverse events
#1	MRS	cladribine	Yes (PR)	Neutropenia
#2	No	No	-	-
#3	No	No	-	-
#4	No	No	-	-
#5	MRS	IFN-2α + cladribine	Yes (PR)	Thrombocytopenia, asthenia
#6	MRS	cladribine	Yes (PR)	No
#7	No	No	-	-
#8	MRS	IFN-2α + hydroxyurea	Yes (PR)	Increased MC-related symptoms
#9	Severe hepatosplenomegaly, MRS	cladribine	Yes (PR)	No
#10	MRS, BP	IFN-2α + cladribine	Yes (PR)	Neutropenia, anemia
#11	MRS	cladribine	Yes (PR)	Pneumonia
#12	Severe splenomegaly, MRS	IFN-2α + cladribine	Yes (PR)	No
#13	No	No	-	-
#14	MRS	IFN-2α + cladribine	Yes (PR)	No
#15	No	No	-	-
#16	Severe organomegaly, MRS	hydroxyurea	Yes (PR)	Thrombocytopenia
#17	AML	idarubicin + cytarabine	No	NA
#18	MRS	hydroxyurea	No	Depression, diarrhea
#19	AML	Yes (NA)	No	Bone marrow failure
#20	Severe organomegaly, MRS	IFN-2α + hydroxyurea	No	Weight loss, nausea, anemia
#21	MRS	hydroxyurea	No	Anemia
#22	MGUS	No	-	-
#23	AML	cladribine + idarubicin + cytarabine	Yes (CR)	Cytopenia, pneumonía, haemorrhages
#24	Severe splenomegaly, MRS	IFN-2α + cladribine	Yes (PR)	Neutropenia, diarrea
#25	MGUS	No	-	-
#26	AML	Yes (NA)	No	NA
#27	AML	Yes (NA)	NA	NA
#28	MRS	hydroxyurea	Yes (PR)	No
#29	AML	idarubicin + cytarabine + mitoxantrone	Yes (PR)	NA
#30	MDS	antithymocyte globulin + ciclosporin	Yes (CR)	Cytopenias
#31	MRS	cladribine	Yes (PR)	Leucopenia
#32	MRS	cladribine	Yes (PR)	No
#33	MRS	IFN-2α + cladribine	Yes (PR)	Nausea
#34	MRS	cladribine	Yes	No

Abbreviations: **AML,** acute myeloid leukemia; **BP**, Severe bone pain secondary to patchy bone sclerosis; **CR,** complete response; **ID,** patient code number used to identify patients analyzed in this study; **MDS,** myelodysplastic syndrome; **MGUS,** monoclonal gammopathy of undetermined significance; **MRS**, severe mast cell mediator–related symptoms refractory to intensive antimediator therapy; **NA,** data on specific therapy not available; **PR,** partial response.

Supplemental Figure S-1. **Proposed clonal hierarchy models for acquisition of different mutations, in addition to *KIT* D816V, in SM patients.** Models A and B represent patients in which *KIT* emerges as the first mutation, on a same cell clone (model A) or in two different clones (model B). Model C represents those patients in which *KIT* and other mutation/s coexist on the same cell populations, but in which *KIT* emerges as a second event after the other mutation/s.

Abbreviations: HPC, hematopoietic precursor cell; LPC, lymphoid precursor cell; MPC, myeloid precursor cell; PPC, pluripotent precursor cell.


A
Mast cells
Neutrophils
MPC
Monocytes
HPC
PPC
Other myeloid cells
LPC
Lymphocytes
KIT mutation
Mutations acquired in MPC
Mutations acquired in Mast cells


B
Mast cells
Neutrophils
MPC
Monocytes
HPC
Other myeloid cells
LPC
Lymphocytes
PPC
Mast cells
Neutrophils
MPC
Monocytes
HPC
Other myeloid cells
LPC
Lymphocytes
KIT mutation
Mutations acquired in MPC


C
Mast cells
Neutrophils
MPC
Monocytes
HPC
PPC
Other myeloid cells
LPC
Lymphocytes
KIT mutation
Mutations acquired prior to KIT